|
TRAXION Products
Neuropathic pain afflicts more than 10 million people
in the US alone and the incidence is set to increase significantly. Sales
of prescription drugs for neuropathic pain are over $5 billion and at 7%
annual growth, it is one of the most rapidly-growing segments of the pain
market.
Traxion has leveraged its relationships with both
local and international groups to build a portfolio of small molecule,
mechanism-based products for the treatment of neuropathic pain. These
products are:
TXT-0200 – orally
active N-type calcium channel antagonist
Late-preclinical, novel, orally active drug which blocks the Cav2.2
(N-type calcium channel) receptor. TXT-0200 has shown promising analgesic
activity in several animal models of neuropathic pain. Compared to
gabapentin, TXT-0200 provides more potent analgesic activity with few
behavioral side effects. Preliminary pharmacokinetic, safety and
toxicology studies have been done and patents filed.
TXT-0400 – highly potent TRPV1
antagonist
Preclinical, novel,
orally active dug which is TRPV1 receptor antagonist. Has shown
particularly potent activity in animal models of chronic and inflammatory
pain. More potent than COX-2 NSAIDs with minimal side effects. Preliminary
pharmacokinetic, safety and toxicology studies have been done and patents
filed.
Traxion Therapeutics Product Portfolio
|
